$-0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)

March 21, 2018 - By Adrian Mccoy

 $ 0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)
Investors sentiment increased to 1.32 in Q3 2017. Its up 0.23, from 1.09 in 2017Q2. It is positive, as 10 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 14 funds opened positions while 15 raised stakes. 59.90 million shares or 5.78% less from 63.58 million shares in 2017Q2 were reported.
Sanctuary Wealth Ltd Co stated it has 2,042 shares or 0.01% of all its holdings. State Street owns 92,375 shares or 0% of their US portfolio. New Leaf Venture Partners Ltd Liability holds 3.96% of its portfolio in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 2.34M shares. 683 Mngmt Ltd Liability holds 2.52 million shares or 0.96% of its portfolio. Excalibur Management accumulated 11,000 shares. Victory holds 0% or 45,040 shares. Jane Street Gru Limited Liability Company reported 14,007 shares stake. Pnc Fincl Serv Grp Inc invested in 0% or 14,000 shares. Polar Ltd Liability Partnership reported 4.13 million shares or 0.17% of all its holdings. Retail Bank Of Mellon accumulated 65,347 shares. Eam Investors Ltd Llc owns 785,338 shares for 0.38% of their portfolio. Bridgeway Capital accumulated 346,464 shares. California Pub Employees Retirement System holds 0% or 33,400 shares. Prelude Capital Mngmt Ltd Company owns 0.03% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 87,709 shares. Deer Vi Co Ltd Co owns 675,242 shares.

Analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $-0.02 EPS on March, 28.They anticipate $0.09 EPS change or 81.82 % from last quarter’s $-0.11 EPS. After having $-0.02 EPS previously, AVEO Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. It closed at $2.91 lastly. It is down 16.67% since March 21, 2017 and is downtrending. It has underperformed by 33.37% the S&P500.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals had 13 analyst reports since March 30, 2016 according to SRatingsIntel. The firm has “Buy” rating by FBR Capital given on Monday, February 12. The stock has “Buy” rating by FBR Capital on Tuesday, January 16. FBR Capital maintained AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Tuesday, March 13 with “Buy” rating. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by Piper Jaffray on Monday, August 28. The firm earned “Buy” rating on Thursday, December 7 by FBR Capital. FBR Capital initiated AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) on Wednesday, March 30 with “Outperform” rating. Piper Jaffray maintained the shares of AVEO in report on Wednesday, August 9 with “Buy” rating. On Monday, June 26 the stock rating was maintained by FBR Capital with “Buy”. The stock has “Overweight” rating by Piper Jaffray on Thursday, May 19. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by Piper Jaffray on Thursday, October 5.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $448.58 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: